RxDoctor Payments Data

Lawrence Dell, MD

Internal Medicine · West Bloomfield, MINPI 1184660490

Payments from drug & device makers

$7,562in general payments, 2019–2025

Across 459 payments — averaging $16.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$880
  • Lilly USA, LLC$783
  • Pfizer$758
  • Novo Nordisk$686
  • GSK$624
  • Teva Pharmaceuticals USA, Inc.$444
  • plus $3K from 34 others

What the payments were for

  • Food & beverage$7,539100%
  • Education$220%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,562 in reported general payments places this provider in the 90th percentile of 4,567 internal medicine providers in Michigan.

See all internal medicine providers in Michigan

Medicare billing

Part B allowed, 2024
$558,362
Medicare patients
1,777
Services billed
14,429

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin125$125,218
OzempicSemaglutide37$71,446
MounjaroTirzepatide53$59,584
XareltoRivaroxaban60$43,904
EliquisApixaban51$42,646
EntrestoSacubitril/Valsartan21$23,797
JanuviaSitagliptin Phosphate21$15,243
MyrbetriqMirabegron12$8,941
Atorvastatin Calcium367$5,248
Levothyroxine Sodium226$2,674
Pantoprazole Sodium68$2,382
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate14$2,292
Ezetimibe30$2,202
Omeprazole146$1,952
Albuterol Sulfate HfaAlbuterol Sulfate46$1,935

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$173$125,218125 claims
Novo NordiskOzempic$686$71,44637 claims
Lilly USA, LLCMounjaro$783$59,58453 claims
Johnson & JohnsonXarelto$442$43,90460 claims
PfizerEliquis$758$42,64651 claims
NovartisEntresto$240$23,79721 claims
MerckJanuvia$46$15,24321 claims
Astellas Pharma US IncMyrbetriq$180$8,94112 claims
AbbVieSynthroid$439$1,36623 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,567 internal medicine providers in Michigan.

Other internal medicine in West Bloomfield

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →